doxycycline

(redirected from Doryx)
Also found in: Dictionary, Thesaurus.

doxycycline

 [dok″sĕ-si´klēn]
a broad-spectrum semisynthetic antibiotic, used as the hyclate and calcium salts against a wide range of gram-positive and gram-negative organisms; administered orally or intravenously.

dox·y·cy·cline

(doks'ē-sī'klēn),
A broad-spectrum antibiotic.

doxycycline

/doxy·cy·cline/ (dok″se-si´klēn) a semisynthetic broad-spectrum tetracycline antibiotic, active against a wide range of gram-positive and gram-negative organisms; used also as d. calcium and d. hyclate.

doxycycline

(dŏk′sĭ-sī′klēn′, -klĭn)
n.
A broad-spectrum antibiotic, C22H24N2O8, derived from tetracycline.

doxycycline

[dok′sisī′klēn]
a tetracycline antibiotic.
indications It is prescribed in the treatment of infections caused by susceptible bacterial strains, especially Chlamydia, Rickettsia, and Mycoplasma.
contraindications Renal or liver dysfunction or known hypersensitivity to this drug or to other tetracycline medication prohibits its use. It is not given during pregnancy or to children less than 8 years of age.
adverse effects Among the more serious adverse reactions are GI disturbances, phototoxicity, potentially serious superinfections, and hypersensitivity reactions. Discoloration of teeth may occur in children exposed to the drug in utero or under 8 years of age.

doxycycline

Infectious disease A broad-spectrum antibiotic used for rickettsiosis–eg, Rocky mountain spotted fever, typhus fever, Q fever, rickettsialpox, tick fevers, RTIs from Mycoplasma pneumoniae, lymphogranuloma venereum, trachoma, inclusion conjunctivitis, etc, due to Chlamydia trachomatis, psittacosis–C psittaci, nongonococcal urethritis–Ureaplasma urealyticum, relapsing fever–Borrelia recurrentis, gram-negative microorganisms: Chancroid–Haemophilus ducreyi, plague–Yersinia pestis, tularemia–Francisella tularensis, cholera–Vibrio cholerae, Campylobacter fetus, Brucella spp, Bartonella bacilliformis, Calymmatobacterium granulomatis, malaria prophylaxis–Plasmodium falciparum in travelers to chloroquine and/or pyrimethamine-sulfadoxine resistant areas Adverse effects GI tract disturbances, anorexia, N&V, diarrhea, glossitis, dysphagia, enterocolitis, anogenital Candida overgrowth, photophobia

dox·y·cy·cline

(doks'ē-sī'klēn)
A broad-spectrum antibiotic.

doxycycline

A tetracycline antibiotic drug, deoxytetracycline, that is well absorbed when taken by mouth, even after food. Doxycycline is also used for the prophylaxis of MALARIA. The drug is on the WHO official list. Brand names are Periostat and Vibramycin.

dox·y·cy·cline

(doks'ē-sī'klēn)
A broad-spectrum antibiotic.

doxycycline

a second-generation, lipid-soluble tetracycline derivative with greater activity against anaerobes and intracellular bacteria, and a longer half-life. Used as the monohydrate.
References in periodicals archive ?
market from Doryx tablets to Doryx capsules so pharmacists would not be
114) By discontinuing its existing versions of Doryx, Warner Chilcott
Doryx capsules and tablets are delayed release oral formulations of doxycycline that can be utilised to treat certain types of infections, such as adjunctive treatment for severe acne and as an anti-malarial.
Specialist pharmaceutical company Warner Chilcott plc (NasdaqGS:WCRX) said on Friday that it has received the US Food and Drug Administration's (FDA) approval for the 200 mg strength of DORYX (doxycycline hyclate) Delayed-Release Tablets.
The company stated that its DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic.
Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is reportedly the generic version of Mayne Pharma's Doryx 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.
The District Court found that the patent is valid and infringed by Mylan's 150 mg generic DORYX product.
The company added Doxycycline Hyclate Delayed-release (DR) Tablets is the first generic version of Mayne Pharma's Doryx (marketed by Warner Chilcott), which is a tetracycline-class antimicrobial.
Speciality pharmaceutical company Impax Laboratories Inc (Nasdaq:IPXL) announced on Wednesday that the US Food and Drug Administration (FDA) has granted final approval of its Abbreviated New Drug Application for the generic version of Doryx (doxycyline hyclate delayed-release) 75mg and 100mg tablets.
KADIAN, SERAX, DORYX and BANTA are registered trade marks of F H Faulding & Co Limited and its controlled entities.
It is equivalent to Doryx capsules from the Parke-Davis division of Warner-Lambert Co.